Vimseltinib (ROMVIMZA™) Gains European Commission (EC) Approval as First Targeted Therapy for TGCT
oncodaily.com/new-paper-al...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vimseltinib #ROMVIMZA #TGCT
Latest posts tagged with #Romvimza on Bluesky
Vimseltinib (ROMVIMZA™) Gains European Commission (EC) Approval as First Targeted Therapy for TGCT
oncodaily.com/new-paper-al...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vimseltinib #ROMVIMZA #TGCT
#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...
Romvimza™ (vimseltinib) is FDA-approved for symptomatic tenosynovial giant cell tumor, where surgery risks serious outcomes. The phase 3 trial showed a 40% ORR vs. 0% for placebo. A promising new option.
📄 Find the clinical evidence for Romvimza at: drugdocs.com/drug/Romvimza
#TGCT #Romvimza #FDA
Vimseltinib (Romvimza): Uses in Cancer, Side effects, Dosage, Expectations, and more
oncodaily.com/drugs/vimsel...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vimseltinib #Romvimza
Ono's ROMVIMZA Approval Disrupts Tenosynovial Giant Cell Tumor Market Dynamics #United_States #Daiichi_Sankyo #Las_Vegas #ROMVIMZA #TGCT
Ono Pharmaceuticals' ROMVIMZA Approval Disrupts TGCT Treatment Market, Challenging TURALIO #None #Tenosynovial #ROMVIMZA #TURALIO